Overview

A Prospective Study of Neoadjuvant Chemotherapy With Gemcitabine/Platinum in Muscle-Invasive or Locally-Advanced Urothelial Carcinoma of Bladder

Status:
Recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

Previously-untreated, high-risk (>T3 and/or N+) muscle-invasive bladder cancer (MIBC) cisplatin 60 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1, 8 and 15. On day 1

Phase:

Phase 2

Details

Lead Sponsor:

Samsung Medical Center

Treatments:

Cisplatin
Gemcitabine